2017
Extended-Release Guanfacine Does Not Show a Large Effect on Tic Severity in Children with Chronic Tic Disorders
Murphy TK, Fernandez TV, Coffey BJ, Rahman O, Gavaletz A, Hanks CE, Tillberg CS, Gomez LI, Sukhodolsky DG, Katsovich L, Scahill L. Extended-Release Guanfacine Does Not Show a Large Effect on Tic Severity in Children with Chronic Tic Disorders. Journal Of Child And Adolescent Psychopharmacology 2017, 27: 762-770. PMID: 28723227, DOI: 10.1089/cap.2017.0024.Peer-Reviewed Original ResearchConceptsExtended-release guanfacineLack of efficacyChronic tic disorderGuanfacine groupPlacebo groupYGTSS total scoreAdverse eventsTotal scoreTic disordersYale Global Tic Severity Scale total scoreClinical Global Impressions-Improvement scaleCommon adverse eventsPlacebo-controlled trialKey secondary outcomesPrimary outcome measureLarger efficacy trialScale total scoreDry mouthSecondary outcomesPreliminary efficacyWeek 8Efficacy trialsOutcome measuresTic severityTourette's disorder
2013
Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies
Nurmi E, Spilman S, Whelan F, Scahill L, Aman M, McDougle C, Arnold L, Handen B, Johnson C, Sukhodolsky D, Posey D, Lecavalier L, Stigler K, Ritz L, Tierney E, Vitiello B, McCracken J. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Translational Psychiatry 2013, 3: e274-e274. PMID: 23799528, PMCID: PMC3693401, DOI: 10.1038/tp.2013.26.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlpha-Ketoglutarate-Dependent Dioxygenase FTOAmidohydrolasesAntipsychotic AgentsBody WeightChildChild Development Disorders, PervasiveChild, PreschoolFemaleGenetic Predisposition to DiseaseHumansLeptinMaleProteinsReceptor, Cannabinoid, CB1Receptor, Melanocortin, Type 4RisperidoneWeight GainConceptsWeight gainAntipsychotic-associated weight gainAntipsychotic-induced weight gainEndocannabinoid metabolic enzymesPrior adult studiesTreatment-naive populationExcessive weight gainHigh-risk groupFatty acid amide hydrolaseTreatment of irritabilityChildren/adolescentsRisperidone studyAntipsychotic exposureAdverse eventsPlasma levelsRisk groupsAdult studiesCannabinoid receptorsNetwork trialAmide hydrolasePharmacogenetic basisGene variantsSignificant riskTrend associationNaive population